Estimating the Monetary Costs of Dementia in the United States (U01 Clinical Trial Not Allowed)

closed

This funding opportunity announcement (FOA) invites U01 applications to develop national cost of illness estimates for the monetary cost of Alzheimers Disease and Alzheimers disease-related dementias (AD/ADRD) in the United States using a societal perspective. The purpose of this FOA is to support development of a national estimate of the costs of AD/ADRD using population-representative and administrative data on older Americans through a comprehensive process that uses a family and People Living With Dementia engagement panel and a Technical Monitoring Committee. Applicants must describe administrative and convening activities - including a Family and People Living With Dementia engagement panel and a Technical Monitoring Committee - to guide cost estimate development and analyses. The awardee under this FOA must establish access to appropriate dataset(s) through NIAs data linkage support contract (MedRIC.info) and analyze the data to develop estimates of costs, including direct and indirect costs. Once data have been analyzed, the awardee will lead development of products to disseminate the methods and findings of the project, through the composition of manuscripts, data briefs, infographics, and presenting the findings of the project to the scientific community. The awardee will administer pilot projects to support cost simulations assessing treatment and policy changes that would alter the cost of disease. Analytic code and products of this work will be shared with the research community.

High